LipoScience, Inc. Logo

LipoScience to Release Fourth Quarter and Fiscal Year 2012 Financial Results

| Source: LipoScience, Inc.

RALEIGH, N.C., March 12, 2013 (GLOBE NEWSWIRE) -- LipoScience, Inc. (Nasdaq:LPDX) today announced that it will release its fourth quarter and fiscal year 2012 financial results after the market close on Wednesday, March 27, 2013. An investor conference call will follow on the same day at 4:30 P.M. ET.

The conference call will be hosted by Richard O. Brajer, President and Chief Executive Officer, and Lucy G. Martindale, Executive Vice President and Chief Financial Officer.

To participate in the call, please dial (877) 303-2523 (U.S. and Canada) or (253) 237-1755 (international). A live webcast will be available on the Investor Relations section of the corporate website at

A replay of the conference call will be available beginning March 27, 2013 at 7:30 p.m. ET and ending on April 10, 2013 by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), Conference ID Number: 20052954. A replay of the webcast will be available on the corporate website for two weeks, through April 10, 2013.

About LipoScience, Inc.

LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the FDA. It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk away automation. The Vantera system will be placed with national and regional clinical laboratories.

LipoScience is driving toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit and

Investor Relations
ICR, Inc.
Bob Yedid
Senior Vice President

LipoScience, Inc.
Tori Hall

(919) 256-1046